TARSUS PHARMACEUTICALS INC. - COMMON STOCK

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

13 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

13 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

06 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

05 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%

17 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024

25 Sep 2024 17:00:00 By Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference

28 Aug 2024 17:00:00 By Nasdaq GlobeNewswire

Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements

08 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

29 Jul 2024 16:30:00 By Nasdaq GlobeNewswire

Tarsus to Participate in Upcoming Investor Conferences

29 May 2024 17:00:00 By Nasdaq GlobeNewswire

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

09 May 2024 17:00:00 By Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

08 May 2024 16:05:01 By Nasdaq GlobeNewswire

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

01 May 2024 17:00:00 By Nasdaq GlobeNewswire

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

23 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Tarsus to Participate at Upcoming Investor Conferences

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

05 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Tarsus Announces Pricing of $100.0 Million Public Offering

01 Mar 2024 00:07:38 By Nasdaq GlobeNewswire

Tarsus Announces Proposed $100.0 Million Public Offering

29 Feb 2024 16:37:35 By Nasdaq GlobeNewswire

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

27 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

22 Feb 2024 08:00:00 By Nasdaq GlobeNewswire